[ NightstaRx raises $45M in Series C ]

NightstaRx has raised $45 million in Series C funding.

Founded in 2013, NightstaRx is a leading retinal gene therapy company focused on developing and commercializing novel, potentially curative one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness, and for which there are no other treatment options.

The Series C proceeds will be used for the upcoming Phase 3 trial for Nightstar’s lead product candidate NSR-REP1 for choroideremia, an ongoing Phase 1/2 clinical trial of Nightstar’s product candidate NSR-RPGR for X-linked retinitis pigmentosa, and a planned Phase 1/2 clinical trial of a gene therapy product candidate for an inherited form of macular dystrophy.

Funding  Series C
Founded  2013
Country  UK
City  London
Founder / CEO  David Fellows
Deal Size  $45M
Investors  New Enterprise Associates
 Syncona Partners LLP.
 Redmile Group
 Wellington Management
Previous Investors  New Enterprise Associates
 Syncona Partners LLP.